Fennec Pharmaceuticals Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $325.5M
- Price
- $11.29
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.53%
- Volume
- 210.7K
About
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc. before officially rebranding as Fennec Pharmaceuticals Inc. in September 2014. Its corporate headquarters are situated in Research Triangle Park, North Carolina.
Quick stats
Shares outstanding34.2M
Computed float22.4M
Float / shares65.6%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001211583
Websitehttps://www.fennecpharma.com
AI Summary
AI-generated1/29
majorbullishearnings
Fennec Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
Fennec Pharmaceuticals reported Q2 2026 net product sales of $17.1 million, up 78% year-over-year, driven by record demand for its lead product PEDMARK and expanded sales force reach.
The company achieved a significant operational milestone, generating non-GAAP Adjusted EBITDA of $2.8 million compared to a loss of $1.2 million in the prior year, alongside GAAP net income of approximately $2.0 million.
Cash position increased to $41.2 million as of June 30, 2026, which management believes is sufficient to fund the business based on current operating plans.